Patents by Inventor Franklin Bymaster

Franklin Bymaster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE COMPOUNDS
    Publication number: 20200039934
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 6, 2020
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Crystalline compounds
    Patent number: 10280141
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 7, 2019
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • CRYSTALLINE COMPOUNDS
    Publication number: 20180194726
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Crystalline compounds
    Patent number: 9856217
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 2, 2018
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
    Patent number: 9839627
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 12, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony McKinney, Frank Gentile, Timothy Hsu, Franklin Bymaster, Walter Piskorski, Richard Welter
  • CRYSTALLINE COMPOUNDS
    Publication number: 20170334850
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 23, 2017
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA, Venkat KUSUKUNTLA
  • USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE DISORDERS INCLUDING NICOTINE ADDICTION
    Publication number: 20170209415
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional anti-addictive compositions in the treatment of nicotine addiction and related disorders.
    Type: Application
    Filed: September 6, 2016
    Publication date: July 27, 2017
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Phil Skolnick
  • Crystalline compounds
    Patent number: 9708261
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 18, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • CRYSTALLINE COMPOUNDS
    Publication number: 20160368871
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA
  • NOVEL METHODS
    Publication number: 20160303076
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Applicant: Neurovance, Inc.
    Inventors: Anthony MCKINNEY, Frank GENTILE, Timothy HSU, Franklin BYMASTER, Walter PISKORSKI, Richard WELTER
  • Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
    Publication number: 20050009925
    Abstract: Selective norepinephrine reuptake inhibitors, particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines, are used for the treatment of cognitive failure, including cognitive failure due to dementia, delirium and schizophrenia.
    Type: Application
    Filed: November 27, 2002
    Publication date: January 13, 2005
    Inventors: Franklin Bymaster, Donald Gehlert, David McKinzie, Charles Yang